Affiliation:
1. Department Мedicine, Kazakhstan Medical University «KSPH», Almaty, Kazakhstan.
2. School of Medicine at the Nazarbayev University, Astana Kazakhstan.
3. Department Public HealthKazakhstan Medical University «KSPH», Almaty, Kazakhstan.
Abstract
Background: Since late 2019, chronic renal disease, which complicates COVID-19 infection, has affected millions globally. Aim: To find key findings, prognosis, associated factors, outcomes, gaps, and recommendations related to COVID-19 in individuals with CKD. Methdology: A narrative review using keywords (COVID-19 OR SARS-CoV-2 OR 2019-nCoV Infections) AND (Chronic Kidney Disease OR CKD OR End-Stage Renal Disease OR Chronic Renal Failure OR Chronic Renal Insufficiency). Results: Analyzed systematic reviews, case-control studies, meta-analyses, observational, retrospective, randomised controlled trials, and case reports. The meta-analysis was conducted using a Random-Effects. The Q-statistic test for heterogeneity was conducted, with 11 degrees of freedom The pooled effect size estimate is 0.6663. The pooled estimate shows a statistically significant impact, with a 95% confidence interval ranging from 0.1834 to 1.1493. Age and comorbidities accelerate disease progression. Scientific Novelity: Briefly discusses how CKD affects COVID-19 patients. Conclusion: CKD greatly increases all-cause mortality and morbidity.